uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings open the ... Genetic Signature May Predict Response ...

During your time with Pathways to Medicine, you will participate in events and activities throughout Year 12 and 13. Every aspect of the programme is designed to help you make a strong and informed ...

Genprex intellectual property and licensing senior vice-president Thomas Gallagher stated: “We continue to bolster our ...

Genprex (GNPX) announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it ...

REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that ... in combination with ALK-inhibitors for ALK-positive lung cancer; Genprex's ability to advance ...

REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of ... REQORSA's potential as a therapeutic treatment in combination ...

You may experience a high white blood cell count with lung cancer due to infections. Medications, such as chemotherapy, may also affect your white blood cell count. Lung cancer begins with lung ...

Identifying gene mutations has paved the way for targeted lung cancer testing and therapies. For example, targeted drug treatment therapies are available, or in development, for the following gene ...